Extracellular membrane vesicles in the three domains of life and beyond

S Gill, R Catchpole, P Forterre - FEMS microbiology reviews, 2019 - academic.oup.com
Cells from all three domains of life, Archaea, Bacteria and Eukarya, produce extracellular
vesicles (EVs) which are sometimes associated with filamentous structures known as …

Global epidemiology of meningococcal disease

LH Harrison, CL Trotter, ME Ramsay - Vaccine, 2009 - Elsevier
As reviewed in this paper, meningococcal disease epidemiology varies substantially by
geographic area and time. The disease can occur as sporadic cases, outbreaks, and large …

Complement control protein factor H: the good, the bad, and the inadequate

VP Ferreira, MK Pangburn, C Cortés - Molecular immunology, 2010 - Elsevier
The complement system is an essential component of the innate immune system that
participates in elimination of pathogens and altered host cells and comprises an essential …

Outer membrane vesicle induction and isolation for vaccine development

MD Balhuizen, EJA Veldhuizen… - Frontiers in …, 2021 - frontiersin.org
Gram-negative bacteria release vesicular structures from their outer membrane, so called
outer membrane vesicles (OMVs). OMVs have a variety of functions such as waste disposal …

The changing and dynamic epidemiology of meningococcal disease

SA Halperin, JA Bettinger, B Greenwood, LH Harrison… - Vaccine, 2012 - Elsevier
The epidemiology of invasive meningococcal disease continues to change rapidly, even in
the three years since the first Meningococcal Exchange Meeting in 2008. Control of disease …

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

J Holst, D Martin, R Arnold, CC Huergo, P Oster… - Vaccine, 2009 - Elsevier
Meningococcal outer membrane proteins have been used for over 20 years in more than 80
million doses; either as carrier protein in a Haemophilus influenzae type b (Hib) …

The development of a vaccine against meningococcus B using reverse vaccinology

V Masignani, M Pizza, ER Moxon - Frontiers in immunology, 2019 - frontiersin.org
The discovery of vaccine antigens through whole genome sequencing (WGS) contrasts with
the classical hypothesis-driven laboratory-based analysis of microbes to identify …

Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

AC Cohn, JR MacNeil, LH Harrison… - Clinical Infectious …, 2010 - academic.oup.com
Abstract Background In January 2005, a quadrivalent (serogroups A, C, Y, and W-135)
meningococcal conjugate vaccine was licensed for use in adolescents. This report …

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised …

ME Santolaya, ML O'Ryan, MT Valenzuela, V Prado… - The Lancet, 2012 - thelancet.com
Background Effective glycoconjugate vaccines against Neisseria meningitidis serogroups A,
C, W-135, and Y have been developed, but serogroup B remains a major cause of severe …

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future

J Holst, P Oster, R Arnold, M Tatley… - Human vaccines & …, 2013 - Taylor & Francis
The utility of wild-type outer membrane vesicle (wtOMV) vaccines against serogroup B
(MenB) meningococcal disease has been explored since the 1970s. Public health …